Topical Ruxolitinib in Chronic Hand Dermatitis
Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair
Sponsor: Incyte Corporation
A PHASE1/PHASE2 clinical study on Chronic Hand Dermatitis, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 10 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
Sep 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .